SCHEMBL1102085

SCHEMBL1102085

COC(=O)Nc1ccc2c(c1)Cc1c-2[nH]c2c(F)c(-c3ccc(N4CCCCC4)cc3)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 7/20 0.57
PARP1 P09874 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.38
TP53 P04637 4/20 0.38
HPGD P15428 1/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
MAPT P10636 3/20 0.37
KMT2A Q03164 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
ALOX15 P16050 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GFER P55789 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102236 0.92 MPL (0.49) MPLPARP1SMN1; SMN2TP53HPGD
SCHEMBL1102077 0.91 MPL (0.69) MPLPARP1SMN1; SMN2TP53NPC1
SCHEMBL1102143 0.90 MPL (0.57) MPLPARP1SMN1; SMN2TP53NPC1
SCHEMBL1102218 0.85 MPL (0.51) MPLPARP1SMN1; SMN2HPGDMAPT
SCHEMBL1102283 0.83 MPL (0.48) MPLSMN1; SMN2TP53HPGDNPC1
SCHEMBL1102202 0.82 MPL (0.84) MPLPARP1
SCHEMBL1102116 0.82 MPL (0.68) MPLPARP1TP53HPGDNPC1
SCHEMBL1102197 0.82 MPL (0.48) MPLPARP1SMN1; SMN2TP53NPC1
SCHEMBL1102210 0.78 MPL (0.46) MPLPARP1SMN1; SMN2HPGDMAPT
SCHEMBL1102281 0.77 MPL (0.74) MPLPARP1NPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO MPL 1/4885PARP1 782/4885SMN1; SMN2 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.